Yes-Associated Protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Tsujiura, Masahiro ^a   Mazack, Virginia ^a   Sudol, Marius ^a,b   Kaspar, Hanna G ^c   Nash, John ^d   Carey, David J ^a   Gogoi, Radhika ^a,d  

^a WEIS CENTER FOR RESEARCH   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Department of Laboratory Medicine Geisinger Medical Laboratories MC 34 60   (United States)

^d GEISINGER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ADULT; AGED; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL INVASION; CELL NUCLEUS; CELL PROLIFERATION; CLONOGENIC ASSAY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CANCER; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MIGRATION INHIBITION; ONCOGENE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RADIOSENSITIVITY; CARCINOSARCOMA; ENDOMETRIUM TUMOR; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; RADIATION DOSE; TUMOR CELL LINE; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; CARCINOSARCOMA; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PHOSPHOPROTEINS; RADIATION TOLERANCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84903398743     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100974     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, et al. (2013) SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute, http://seer.cancer.gov/csr/1975-2010/, [Based on the November 2012 SEERdata submission, posted to the SEER web site, April 2013. http://seer.cancer.gov/ statfacts/html/corp.html].
3. Fader AN, Arriba LN, Frasure HE, von Gruenigen VE (2009) Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 114: 121-127.
4. Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, et al. (2012) FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One 7: e30801.
5. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, et al. (1997) Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57: 3935-3940. (Pubitemid 27427679)
6. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, et al. (2011) A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 17: 1331-1340.
7. Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, et al. (2008) Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A 105: 8713-8717. (Pubitemid 351987745)
8. Clement PB, Young RH (2002) Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 9: 145-184.
9. Clement PB, Young RH (2004) Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 11: 117-142.
10. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, et al. (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40: 55-65.
11. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, et al. (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355: 1404-1411. (Pubitemid 30215963)
12. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, et al. (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92: 744-751. (Pubitemid 38251372)
13. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, et al. (2003) Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 89: 201-209. (Pubitemid 36457866)
14. Sudol M (1994) Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 9: 2145-2152.
15. Sudol M, Gelman IH, Zhang J (2013) YAP1 Uses Its Modular Protein Domains and Conserved Sequence Motifs to Orchestrate Diverse Repertoires of Signaling. The Hippo Signaling Pathway and Cancer: Springer. pp. 53-70.
16. Zhao B, Ye X, Yu J, Li L, Li W, et al. (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22: 1962-1971. (Pubitemid 352008643)
17. Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, et al. (2009) YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol 11: 1444-1450.
18. Wang H, Du YC, Zhou XJ, Liu H, Tang SC (2013) The dual functions of YAP-1 to promote and inhibit cell growth in human malignancy. Cancer Metastasis Rev.
19. Harvey KF, Zhang X, Thomas DM (2013) The Hippo pathway and human cancer. Nat Rev Cancer 13: 246-257.
20. Oka T, Mazack V, Sudol M (2008) Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J Biol Chem 283: 27534-27546.
21. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, et al. (2006) Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 103: 12405-12410. (Pubitemid 44267272)
22. Muramatsu T, Imoto I, Matsui T, Kozaki K, Haruki S, et al. (2011) YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis 32: 389-398.
23. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, et al. (2006) Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125: 1253-1267. (Pubitemid 43929093)
24. Modena P, Lualdi E, Facchinetti F, Veltman J, Reid JF, et al. (2006) Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 24: 5223-5233. (Pubitemid 46631366)
25. Yokoyama T, Osada H, Murakami H, Tatematsu Y, Taniguchi T, et al. (2008) YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis 29: 2139-2146.
26. Fernandez LA, Northcott PA, Dalton J, Fraga C, Ellison D, et al. (2009) YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev 23: 2729-2741.
27. Wang L, Shi S, Guo Z, Zhang X, Han S, et al. (2013) Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One 8: e65539.
28. Kang W, Tong JH, Chan AW, Lee TL, Lung RW, et al. (2011) Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res 17: 2130-2139.
29. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, et al. (2009) Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115: 4576-4585.
30. Wang Y, Dong Q, Zhang Q, Li Z, Wang E, et al. (2010) Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 101: 1279-1285.
31. Hall CA, Wang R, Miao J, Oliva E, Shen X, et al. (2010) Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res 70: 8517-8525.
32. Zhang X, George J, Deb S, Degoutin JL, Takano EA, et al. (2011) The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 30: 2810-2822.
33. Dhananjayan SC, Ramamoorthy S, Khan OY, Ismail A, Sun J, et al. (2006) WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors. Mol Endocrinol 20: 2343-2354. (Pubitemid 44496405)
34. Fernandez LA, Squatrito M, Northcott P, Awan A, Holland EC, et al. (2012) Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene 31: 1923-1937.
35. Creasman W (1989) Announcement, FIGO stages 1988, revisions. Gynecol Oncol 35: 7.
36. Mutch DG (2009) The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecologic oncology 115: 325-328.
37. Singh M, Spoelstra NS, Jean A, Howe E, Torkko KC, et al. (2008) ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol 21: 912-923. (Pubitemid 351896667)
38. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK (2009) MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8: 1055-1066.
39. Albitar L, Pickett G, Morgan M, Davies S, Leslie KK (2007) Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells. Gynecol Oncol 106: 52-64. (Pubitemid 46898570)
40. Nishimura Y, Komatsu S, Ichikawa D, Nagata H, Hirajima S, et al. (2013) Overexpression of YWHAZ relates to tumor cell proliferation and malignant outcome of gastric carcinoma. Br J Cancer 108: 1324-1331.
41. Sudol M (2013) YAP1 oncogene and its eight isoforms. Oncogene 32: 3922.
42. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, et al. (2008) Expression of Yes-associated protein in common solid tumors. Hum Pathol 39: 1582-1589.
43. Zhao B, Wei X, Li W, Udan RS, Yang Q, et al. (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21: 2747-2761. (Pubitemid 350070721)
44. Dong J, Feldmann G, Huang J, Wu S, Zhang N, et al. (2007) Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130: 1120-1133. (Pubitemid 47410268)
45. Aylon Y, Michael D, Shmueli A, Yabuta N, Nojima H, et al. (2006) A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev 20: 2687-2700. (Pubitemid 44498379)
46. Tschop K, Conery AR, Litovchick L, Decaprio JA, Settleman J, et al. (2011) A kinase shRNA screen links LATS2 and the pRB tumor suppressor. Genes Dev 25: 814-830.
47. Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, et al. (2009) Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A 106: 4834-4839.
48. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497: 67-73.
49. Pawlik TM, Keyomarsi K (2004) Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59: 928-942. (Pubitemid 38834285)
50. Pajonk F, Vlashi E, McBride WH (2010) Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 28: 639-648.